Clinical benefit from these agents is in part limited by hyperphosphatemia owing to FGFR1 inhibition, as well as the emergence of resistance mutations in FGFR genes, activation of bypass signaling pathways, concurrent TP53 alterations, and possibly, epithelial–mesenchymal transition-related isoform switching. This evidence concerns the gene TP53 and hyperphosphatemia.